HHS awarded Merck $1.45B for vaccines, with 7 bids received under full and open competition

Contract Overview

Contract Amount: $1,453,663,190 ($1.5B)

Contractor: Merck Sharp & Dohme LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2017-04-01

End Date: 2018-03-31

Contract Duration: 364 days

Daily Burn Rate: $4.0M/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 7

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: IGF::OT::IGF 2017 VACCINES FOR CHILDREN

Place of Performance

Location: WHITEHOUSE STATION, HUNTERDON County, NEW JERSEY, 08889

State: New Jersey Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $1.45 billion to MERCK SHARP & DOHME LLC for work described as: IGF::OT::IGF 2017 VACCINES FOR CHILDREN Key points: 1. The contract value represents a significant investment in public health, specifically vaccine procurement. 2. Full and open competition suggests a robust market for vaccine manufacturing, potentially leading to better pricing. 3. The firm-fixed-price structure provides cost certainty for the government. 4. The duration of the contract (one year) indicates a need for ongoing vaccine supply. 5. The award to a single contractor, Merck, highlights its established role in vaccine production. 6. The geographic location of the contractor (New Jersey) may have implications for domestic supply chain resilience.

Value Assessment

Rating: good

The contract value of $1.45 billion for vaccines is substantial. Benchmarking this against similar large-scale vaccine procurements by the government would be necessary for a precise value-for-money assessment. However, the presence of multiple bidders (7) in a full and open competition suggests that the pricing was likely competitive. The firm-fixed-price nature of the award also contributes to predictable costs for the agency.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, with seven bids received. This indicates a healthy level of market interest and a competitive environment for vaccine manufacturing. The multiple bids suggest that the government had several viable options, which typically drives down prices and improves the quality of goods or services offered.

Taxpayer Impact: The extensive competition for this vaccine contract is beneficial for taxpayers as it likely resulted in a more favorable price than a sole-source or limited competition award. It demonstrates that taxpayer funds are being used efficiently by leveraging market forces.

Public Impact

The primary beneficiaries are the recipients of the vaccines, contributing to public health and disease prevention. The services delivered include the supply of essential vaccines, crucial for national immunization programs. The geographic impact is national, ensuring vaccine availability across the United States. The workforce implications are primarily within the pharmaceutical manufacturing sector, supporting jobs at Merck and its suppliers.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single supplier for critical vaccines.
Vulnerability to supply chain disruptions affecting Merck's manufacturing capabilities.
Limited visibility into the specific vaccine types procured without further detail.

Positive Signals

Awarded through full and open competition, indicating a competitive process.
Firm-fixed-price contract provides cost certainty.
Significant investment in public health infrastructure through vaccine procurement.

Sector Analysis

The pharmaceutical and biotechnology sector is characterized by high R&D costs, stringent regulatory requirements, and significant market concentration among a few large players. This contract falls within the 'Medicinal and Botanical Manufacturing' industry code. Government procurement of vaccines is a critical component of public health, often involving large dollar values and long-term relationships with manufacturers. Comparable spending benchmarks would involve looking at other large-scale vaccine procurements by HHS or the Department of Defense.

Small Business Impact

There is no indication of a small business set-aside for this contract, nor is there information on subcontracting plans. Given the scale and nature of vaccine manufacturing, it is likely that the prime contractor, Merck, possesses the specialized capabilities and infrastructure required. The impact on the small business ecosystem would likely be indirect, through potential supply chain opportunities if Merck engages small businesses as vendors.

Oversight & Accountability

Oversight for this contract would primarily fall under the Centers for Disease Control and Prevention (CDC) within HHS. Accountability measures would include adherence to delivery schedules, quality control of the vaccines, and compliance with contract terms. Transparency is generally maintained through contract award databases, though specific details of vaccine types and quantities may be sensitive. The HHS Office of Inspector General (OIG) would have jurisdiction for investigating fraud, waste, and abuse related to this contract.

Related Government Programs

Vaccines for Children Program
Strategic National Stockpile
HHS Public Health Emergency Fund
Department of Defense Vaccine Procurement

Risk Flags

Potential for supply chain disruption
Dependence on a single manufacturer
Price volatility in future procurements

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $1.45 billion to MERCK SHARP & DOHME LLC. IGF::OT::IGF 2017 VACCINES FOR CHILDREN

Who is the contractor on this award?

The obligated recipient is MERCK SHARP & DOHME LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $1.45 billion.

What is the period of performance?

Start: 2017-04-01. End: 2018-03-31.

What is Merck Sharp & Dohme LLC's track record with federal vaccine contracts?

Merck Sharp & Dohme LLC, a major pharmaceutical company, has a long-standing history of supplying vaccines to the U.S. government. They are a key provider for programs like the Vaccines for Children (VFC) program and have secured numerous contracts over the years for various vaccines, including those for influenza, HPV, and pneumococcal disease. Their extensive experience and established manufacturing capabilities position them as a primary contractor for large-scale federal vaccine procurements. Data on past contract performance, including delivery success rates and any quality issues, would be available through federal procurement databases and agency performance reports, though specific details for every contract may not be publicly accessible.

How does the $1.45 billion contract value compare to historical federal vaccine spending?

The $1.45 billion awarded to Merck represents a significant, but not unprecedented, investment in vaccine procurement. Federal spending on vaccines fluctuates annually based on public health needs, emerging diseases, and the specific vaccines being purchased (e.g., annual flu shots versus multi-year procurements for new vaccines). For context, the CDC's overall budget for vaccine procurement can run into billions of dollars annually. This specific contract, awarded in 2017 for a one-year period, likely covers a substantial quantity of specific vaccines. To provide a precise comparison, one would need to analyze historical spending data for similar vaccine types and contract durations from agencies like the CDC and the Department of Defense over several years.

What are the primary risks associated with a large federal vaccine contract awarded to a single manufacturer?

A primary risk is supply chain vulnerability; any disruption at Merck's manufacturing facilities, due to natural disasters, labor issues, or unforeseen production problems, could impact the availability of critical vaccines nationwide. Another risk is potential price escalation in future contracts if competition diminishes or if Merck faces increased production costs. There's also the risk of over-reliance, where the government becomes heavily dependent on one supplier, potentially limiting its negotiating leverage. Furthermore, if the contract is for a specific vaccine, and a new, more effective alternative emerges, the government might be locked into purchasing a less optimal product until the contract expires.

How effective is the 'full and open competition' strategy in ensuring value for taxpayer money in vaccine procurement?

Full and open competition is generally considered the most effective strategy for ensuring value for taxpayer money in procurement, including for vaccines. By allowing all responsible sources to submit bids, the government maximizes the pool of potential suppliers, fostering a competitive environment. This competition typically drives down prices, encourages innovation, and ensures that the government receives high-quality products or services at the best possible cost. In the case of vaccines, having multiple manufacturers compete can lead to more favorable pricing and ensure a more resilient supply chain, as the government is not solely reliant on one entity. The presence of seven bidders in this specific contract underscores the effectiveness of this approach.

What are the implications of the 'firm fixed price' contract type for this vaccine award?

A firm fixed price (FFP) contract type means that the price is set and not subject to adjustment based on the contractor's cost experience. For the government, this offers significant cost certainty and predictability, making budgeting easier and protecting against cost overruns. The contractor, Merck, assumes the risk of any cost increases during performance. This is generally advantageous for the government when the scope of work is well-defined and the risks of cost escalation are manageable, as is often the case with established vaccine manufacturing. It incentivizes the contractor to control costs efficiently to maintain profitability.

What is the typical duration for federal vaccine supply contracts, and how does this one compare?

Federal vaccine supply contracts can vary significantly in duration. Some may be for a single year, particularly for seasonal vaccines like influenza, or for specific quantities needed within a defined period. Others can be multi-year agreements, often for newer vaccines or those required for long-term public health initiatives, providing more stability for both the government and the manufacturer. This contract, with a duration of 364 days (approximately one year), is typical for procurements where the need is ongoing but may be subject to annual review, re-competition, or adjustments based on evolving public health recommendations or vaccine availability. It allows for flexibility while ensuring a consistent supply.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Medicinal and Botanical Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 2017N18099

Offers Received: 7

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Merck & CO., Inc.

Address: ONE MERCK DRIVE, WHITEHOUSE STATION, NJ, 08889

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $2,296,282,739

Exercised Options: $2,296,282,739

Current Obligation: $1,453,663,190

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NOT OBTAINED - WAIVED

Timeline